- Utrecht, Nederland
- 27 november 2024
PhD candidate focusing on improving allogeneic hematopoietic cell transplantation and chimeric antigen receptor (CAR) T cell therapy in pediatric patients with acute leukemia by looking at clinical parameters, tumor-intrinsic features and the functional dynamics of the immune system. In this project, I combine wet-lab assays with big data analysis in the programming language R. I look forward to continuing doing research in the field of translational immuno-oncology, thereby expanding my knowledge and contributing to the field and patient outcomes. I am also highly passionate about sex- and gender-based medicine, which I would like to implement in my future career. I would describe myself as ambitious, eager to learn, enthusiastic, and accountable.
Opleiding
Ervaring
With immunological assays and flow cytometry, we use in vitro models and patient material to study outcome predictors and potential improvements for allogeneic hematopoietic cell transplantation and CAR T cell therapy in pediatric patients with high-risk hematological malignancies.
Using cell culture, western blot, qPCR and mouse xenograft models, the sensitivity of novel Hippo pathway inhibitors targeting YAP in hepatocarcinoma was studied.Off target effects of these small molecule inhibitors were tested and ‘on target’ engagement was validated.
1) With the smMIP approach and subsequent sequencing, we characterized germline mutations in genes linked to asparaginase enzyme activity and host toxicity in pediatric acute lymphoblastic leukemia.
2) With PCR, qPCR and Sanger sequencing, we determined the relevance of subclonal IKZF1 deletions encompassing exon 4 to 7 for relapse development in pediatric acute lymphoblastic leukemia